AB&B BIO-TECH-B (02627): China Drug Administration Center approves MRNA RSV vaccine IND application.

AB&B BIO-TECH-B (02627) announced that following the approval by the Food and Drug Administration of the United States on November 7, 2025 for its new drug clinical trial application submitted in the United States, the National Medical Products Administration Drug Evaluation Center has approved the group's investigational new drug application for its mRNA RSV vaccine candidate product. RSV is a common virus that causes respiratory infections, especially in susceptible populations such as the elderly and those with chronic illnesses, which can develop into severe cases such as bronchiolitis or pneumonia. Currently in China, the treatment for RSV infection relies on broad-spectrum antiviral drugs and symptom management. Therefore, there is an urgent need to develop an effective RSV vaccine. mRNA vaccines have shown to induce strong cellular immune responses and long-lasting humoral immunity in clinical studies, making it a promising choice to protect elderly and immunocompromised individuals from severe lower respiratory tract infections caused by RSV.